After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers

Doctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.

statnews.com

NSF testing new Ph.D. model giving trainees academic and industry experience

Young life scientists have been increasingly abandoning academia, a seismic shift that has fueled calls for rethinking graduate education. On Wednesday,

statnews.com

Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx

Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market

statnews.com

Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn

A Trump administration plan to limit visas for graduate student and postdocs to four years is fueling concerns that the U.S. could lose out on foreign scientists

statnews.com

White House offers its science blueprint: More AI, less life sciences

The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.

statnews.com

Trump taps former public health leader Erica Schwartz to run CDC

Schwartz's background as a physician with plenty of government service experience will likely be popular among lawmakers.

statnews.com

ACIP conflict is test of Trump's support for RFK Jr.'s vaccine policy overhaul

The Trump administration is weighing how to respond to a court ruling on vaccine policymaking, a decision that could come with political risks.

statnews.com

National survey of NIH-funded researchers shows precarious state of U.S. science — ‘This is like the Titanic’

A nationwide STAT survey of NIH-funded researchers reveals that, a year after Donald Trump's return to the White House, many scientists are reeling

statnews.com

FDA’s top infectious disease regulator to depart agency

Adam Sherwat, the director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, is leaving the agency.

statnews.com

NIH will spend its full budget this year, agency director promises House appropriators

NIH Director Jay Bhattacharya promised a House subcommittee on Tuesday that the agency will spend its full budget by the end of the 2026 fiscal year

statnews.com

Federal judge stalls health secretary RFK Jr.’s overhaul of vaccine policy

Breaking: A federal judge on Monday stalled major parts of health secretary Robert F. Kennedy Jr.’s campaign to remake vaccine policy in the U.S.

statnews.com

5 lessons from Vinay Prasad's turbulent tenure at the FDA

Vinay Prasad's unique ability to attract criticism — even when his bosses, including the president, wanted him to keep his head low — did him in at the FDA.

statnews.com

Vinay Prasad, key Makary ally and a focus of controversy at FDA, is leaving the agency

Prasad has been involved in several controversial decisions related to rare disease treatments.

statnews.com

A month in, TrumpRx falls short of president’s grand promises

Trump wants to focus on his efforts to lower drug prices, but the TrumpRx website is falling short of his promises.

statnews.com

A new mystery emerges about Epstein's involvement in Harvard genetics study

Someone seems to have altered the Personal Genome Project’s profile page believed to belong to Epstein to indicate he provided consent to join the study Jan. 31, 2026.

statnews.com

2026 STAT Madness

2026 bracket Welcome to STAT Madness, a bracket-style contest to find the best innovation in science and medicine. Explore groundbreaking innovations from

statnews.com

A titan of vaccine development sees his field’s achievements slip away

Stanley Plotkin, the 93-year-old "godfather of vaccines," is watching his field’s achievements slip away.

statnews.com

FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay Prasad, in an interview with CNBC.

statnews.com

A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA

Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it.

statnews.com

Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church

Exclusive: Harvard geneticist George Church knew more about Jeffrey Epstein's activities than he has previously said, before accepting new donations from the sex offender.

statnews.com

Nature Medicine to investigate study that found cancer treatment is better in morning

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

statnews.com

With federal research funding uncertain, states debate new science initiatives

A handful of states are considering initiatives to increase funding for scientific research as uncertainty around federal dollars has grown.

statnews.com

Key study of Grail’s cancer detection test fails in setback for company

A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant study being conducted with

statnews.com

N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up

nytimes.com

STAT wins fourth Polk Award for reporting on impact of Trump on health

STAT has won its fourth Polk Award in five years for documenting the Trump administration’s shakeup of the FDA, scientific research, and public health.

statnews.com

FDA reverses course, agrees to review Moderna’s flu vaccine

The FDA reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.

statnews.com